Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor PEDIATRICS – Jane Lee Chiang, MD, and Georgeanna J. Klingensmith, MD ADULTS – Irl B. Hirsch, MD 1. Basal insulin accounts for ~50% of total daily dose: i. LAA (insulin glargine, detemir, degludec) or NPH if LAA …
Read More »What Do We Know about the Dawn Phenomenon?
Can basal insulin can make a difference?…
Read More »Risk Factors for Hypoglycemia and Strategies for Avoidance
Minimizing hypoglycemia in type 2 diabetes patients…. Hypoglycemia is a common problem among patients taking combinations of insulin and sulfonylureas and may be a limiting factor in diabetes therapy management. Hypoglycemia is defined by the American Diabetes Association (ADA) as a plasma glucose of 79mg/dL. (3.9mmol/L) or less; however most people …
Read More »Is Linagliptin Safe for the Elderly?
New research assesses safety and efficacy of linagliptin as add on treatment in elderly diabetes patients….
Read More »Exenatide: Once Weekly Dosing or Twice Daily?
Does Bydureon once weekly show benefit in type 2 diabetic patients?…
Read More »New Direction in Drug Treatment Selection for Type 2 Diabetes
Scientific understanding of the disease shifts treatment to drugs with newer mechanisms….
Read More »Impact of the Dawn Phenomenon on Type 2 Diabetes Patients
About 50% of patients experience the dawn phenomenon….
Read More »Dapagliflozin Provides Additional Benefit as Add-On to Sitagliptin
In earlier clinical trials dapagliflozin consistently reduced HbA1c in treatment-naive patients….
Read More »Cyrus Desouza, MBBS, Q6: Prescribing Sulfonylureas
Dr. Cyrus Desouza, MBBS, reveals the dark secret behind why patients still use sulfonylureas. Although very effective inititally, the drug is only effective for a limited amount of time and there is beta cell burnout. Dr. Desouza tries not to start patients on sulfonylureas as a second-line; instead he’d rather start with basal …
Read More »Sulfonylurea’s Cardiotoxicity Probed
The risk of ischemic events may be higher with a specific subclass of sulfonylureas….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.